CRDF (NASDAQ) - 30-Min Chart Long Trade Setup !🚀
🔍 Stock: CRDF (NASDAQ)
⏳ Timeframe: 30-Min Chart
📈 Setup Type: Bullish Breakout
📍 Trade Plan:
✅ Entry Zone: Above $4.40 - $4.45 (Breakout Confirmation)
🟢 Take Profit 1 (TP1): $4.58 (First Resistance Target)
🟢 Take Profit 2 (TP2): $4.82 (Extended Bullish Target)
🚀 Stop-Loss (SL): Below $4.21 (Key
Cardiff Oncology, Inc.
No trades
No trades
Peers for comparison
−0.5385 USD
−45.85 M USD
593.00 K USD
73.00 M
Last report date
Report period
EPS
Revenue
Company info
Sector
Industry
CEO
Mani Mohindru
Website
Headquarters
San Diego
Founded
1999
IPO date
Jul 27, 2004
ISIN
US14147L1089
CUSIP
14147L108
FIGI
BBG000PXLKM7
Identifiers
ISIN US14147L1089
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The firm is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
CRDF (NASDAQ) - 30-Min Chart Long Trade Setup! 🚀
🔍 Stock: CRDF (NASDAQ)
⏳ Timeframe: 30-Min Chart
📈 Setup Type: Bullish Breakout
📍 Trade Plan:
✅ Entry Zone: Above $4.70 - $4.75 (Breakout Confirmation)
🚀 Take Profit 1 (TP1): $4.83 (First Resistance)
🚀 Take Profit 2 (TP2): $5.01 (Extended Bullish Target)
🔻 Stop-Loss (SL): Below $4.53 (Key Suppor
CRDF (NASDAQ) - 30-Min Chart Long Trade Setup! 🚀
🔍 Stock: CRDF (NASDAQ)
⏳ Timeframe: 30-Min Chart
📈 Setup Type: Bullish Breakout
📍 Trade Plan:
✅ Entry Zone: Above $4.61 - $4.65 (Breakout Confirmation)
🚀 Take Profit 1 (TP1): $4.86 (First Resistance)
🚀 Take Profit 2 (TP2): $5.07 (Extended Bullish Target)
🔻 Stop-Loss (SL): Below $4.43 (Key Suppor
Cardiff Oncology Inc 🧙Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
If yo
See all ideas
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
Today, CRDF trades at 0.8516 USD.
For broader market analysis, dive into the technicals on the Cardiff Oncology, Inc. stock price chart and read the latest CRDF news:
– CRDF: Phase II response and durability signals underpin a planned pan-RAS colorectal cancer phase III trial
– Cardiff Oncology (CRDF) Gets FDA Fast Track for Onvansertib
– Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
For broader market analysis, dive into the technicals on the Cardiff Oncology, Inc. stock price chart and read the latest CRDF news:
– CRDF: Phase II response and durability signals underpin a planned pan-RAS colorectal cancer phase III trial
– Cardiff Oncology (CRDF) Gets FDA Fast Track for Onvansertib
– Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
Markets don't sleep, here's what's going on with CRDF at the moment:
– CRDF: Phase II response and durability signals underpin a planned pan-RAS colorectal cancer phase III trial
– Cardiff Oncology (CRDF) Gets FDA Fast Track for Onvansertib
– Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
See more updates in real-time with our News Flow.
– CRDF: Phase II response and durability signals underpin a planned pan-RAS colorectal cancer phase III trial
– Cardiff Oncology (CRDF) Gets FDA Fast Track for Onvansertib
– Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
See more updates in real-time with our News Flow.
Cardiff Oncology, Inc. is scheduled to release its next earnings report on Mar 4, 2027.
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
CRDF stock is 7.23% volatile and has beta coefficient of 2.80.
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like CRDF are typically less volatile than smaller companies
Track every detail on Cardiff Oncology, Inc. stock chart and check out the list of the most volatile stocks — is Cardiff Oncology, Inc. there?
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like CRDF are typically less volatile than smaller companies
Track every detail on Cardiff Oncology, Inc. stock chart and check out the list of the most volatile stocks — is Cardiff Oncology, Inc. there?
To understand the CRDF stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — −0.87%
– 1 week — +7.56%
– 1 month — −8.80%
CRDF all-time low was 0.7010 USD (Mar 19, 2020), and its highest price is 2,031.2122 USD (Jun 10, 2005). Find more dynamics in the Stock Heatmap and on the Cardiff Oncology, Inc. stock chart.
– 1 day — −0.87%
– 1 week — +7.56%
– 1 month — −8.80%
CRDF all-time low was 0.7010 USD (Mar 19, 2020), and its highest price is 2,031.2122 USD (Jun 10, 2005). Find more dynamics in the Stock Heatmap and on the Cardiff Oncology, Inc. stock chart.
Cardiff Oncology, Inc. market capitalization is 65.27 M, representing the total value of all its outstanding shares (price × shares outstanding).
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Cardiff Oncology, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Cardiff Oncology, Inc. stacks up against other companies
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Cardiff Oncology, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Cardiff Oncology, Inc. stacks up against other companies
The safest way to buy Cardiff Oncology, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.
You can trade CRDF directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
You can trade CRDF directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 19, 2026, the company has 31 employees.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Investing in Cardiff Oncology, Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.
First, study Cardiff Oncology, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our CRDF technicals – signals based on essential indicators calculations:
– Today — neutral
– 1-week — sell
– 1-month — sell
Combine fundamental and technical analysis for better results.
First, study Cardiff Oncology, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our CRDF technicals – signals based on essential indicators calculations:
– Today — neutral
– 1-week — sell
– 1-month — sell
Combine fundamental and technical analysis for better results.
Cardiff Oncology, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Cardiff Oncology, Inc. stocks trade under the symbol CRDF.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
CRDF earnings for the last quarter are −0.12 USD per share, whereas the estimation was −0.14 USD, resulting in a 13.02% surprise. The estimated earnings for the next quarter are −0.13 USD per share.
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Cardiff Oncology, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Cardiff Oncology, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Cardiff Oncology, Inc. revenue for the last quarter amounts to 171.00 K USD despite the estimated figure of 81.43 K USD. In the next quarter revenue is expected to reach 93.57 K USD.
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Cardiff Oncology, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Cardiff Oncology, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
Yes, you can track Cardiff Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
CRDF net income for the last quarter is −8.86 M USD, while the quarter before that showed −9.23 M USD of net income which accounts for 4.06% change.
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Cardiff Oncology, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Cardiff Oncology, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Cardiff Oncology, Inc. does not currently pay dividends to its shareholders.
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
CRDF reached its all-time high of 2,031.2122 USD on Jun 10, 2005. Its all-time low was 0.7010 USD and was reached on Mar 19, 2020.
Explore the Cardiff Oncology, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Explore the Cardiff Oncology, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Cardiff Oncology, Inc. EBITDA is −38.62 M USD, with an EBITDA margin of −8.10 K%.
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Cardiff Oncology, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Cardiff Oncology, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 1.20 USD and 9.00 USD for CRDF, based on current estimates.
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance









